Financial & competing interests disclosure
The views in this article are the personal views of the authors and do not necessarily represent the views of the professional organizations or institutions within which we are members. Gregory Poland is the chair of a Safety Evaluation Committee for an investigational influenza peptide vaccine trial being conducted by Merck Research Laboratories. Gregory Poland offers consultative advice on new vaccine development to Novartis Vaccines, Merck & Co., Inc., Avianax, GlaxoSmithKline, Theraclone Sciences, Liquidia Technologies, Inc., Emergent BioSolutions and Novavax. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.